News from the Broad

The Broad Institute is committed to open sharing not only of its scientific data and tools, but also information and news about our progress towards achieving our mission. Below are just a few highlights from the Broad scientific community.
  • First glimpse of schizophrenia’s genetic roots shines light on a developmental process gone awry

    January 26th, 2016
    Groundbreaking work is the result of analytical ingenuity, fortuitous collaborations, and catalytic philanthropic funding
    Read Full Story
  • Genetic study provides first-ever insight into biological origin of schizophrenia

    January 26th, 2016
    Landmark analysis reveals excessive “pruning” of connections between neurons in brain predisposes to schizophrenia
    Read Full Story
  • Compendium of immune signatures to improve Gene Set Enrichment Analysis

    January 26th, 2016

    Researchers Nick Haining and Jernej Godec of Dana-Farber Cancer Institute, Harvard Medical School, and Broad Institute collaborated with Broad and UC San Francisco computational biologists to build a collection of gene signatures from different immune cell types and perturbations. The collection, called ImmuneSigDB, includes almost 5,000 new gene sets and has been added to MSigDB. The additions are expected to greatly improve the use of Gene Set Enrichment Analysis for immunological studies; in a paper published by the journal Immunity, the team uses the collection to identify species-specific and shared aspects of the biology of the immune response to sepsis between mice and humans.

  • Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib)

    January 22nd, 2016
    Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one...
    Read Full Story
  • Stuart Schreiber receives 2016 Wolf Prize in Chemistry

    January 14th, 2016
    Broad Institute core member receives 2016 Wolf Prize for his fundamental contributions to the field of chemical biology
    Read Full Story